Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity

Carbidopa is a drug that blocks conversion of levodopa to dopamine outside of central nervous system (CNS) and thus inhibits unwanted side effects of levodopa on organs located outside of CNS during management of Parkinson’s Disease (PD). PD is associated with increased expression of inflammatory ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huabin, Lemos, Henrique, Bhatt, Brinda, Islam, Bianca N., Singh, Abhijit, Gurav, Ashish, Huang, Lei, Browning, Darren D., Mellor, Andrew, Fulzele, Sadanand, Singh, Nagendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595290/
https://www.ncbi.nlm.nih.gov/pubmed/28898256
http://dx.doi.org/10.1371/journal.pone.0183484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595290/
https://www.ncbi.nlm.nih.gov/pubmed/28898256
http://dx.doi.org/10.1371/journal.pone.0183484

Ejemplares similares